EpiCast Report: Amyotrophic Lateral Sclerosis - Epidemiology Forecast to 2023

Publisher Name :
Date: 01-May-2014
No. of pages: 38

Amyotrophic lateral sclerosis (ALS), often referred to as "Lou Gehrig's Disease," is a rare, but fatal, progressive neurodegenerative disease that affects the nerve cells in the brain and the spinal cord. ALS severely impacts physical functioning and initially presents with muscle twitching, weakness in an arm or leg, or with slurring of speech. Eventually, people with ALS lose their ability to control the muscles needed to move, speak, eat, and breathe, which ultimately leads to death. The progressively degenerative course of the condition is a great burden for both patients and caregivers, as well as for society.

GlobalData epidemiologists forecast that the diagnosed prevalent cases of ALS in the 7MM will grow by 13.5% over the next decade, from 32,698 diagnosed prevalent cases in 2013 to 37,122 diagnosed prevalent cases in 2023. Throughout the forecast period, the US will have the highest numbers of diagnosed prevalent cases of ALS, followed by Japan.

To develop the epidemiological forecast for the diagnosed prevalent cases of ALS in the 7MM, GlobalData epidemiologists obtained the diagnosed prevalence data for ALS from peer-reviewed journals and population-based studies in the respective markets and used a consistent methodology to ensure comparability of the results. A major strength of GlobalData's epidemiological analysis is the use of country-specific studies that provided the diagnosed prevalence of ALS using uniform diagnostic criteria based on the El Escorial criteria or the International Classification of Diseases, Ninth Revision (ICD-9), criteria (ICD-9 code for ALS = 335.2), to allow for a meaningful comparison of the diagnosed prevalent cases of ALS in these markets. Furthermore, the diagnosed prevalent cases of ALS in each of the 7MM were further segmented by age and sex in order to provide a more detailed analysis of the patient population.

Scope


  • The Amyotrophic lateral sclerosis (ALS) EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for ALS in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed prevalent cases of ALS segmented by age (=40 years) and sex in these markets.

  • The ALS epidemiology report is written and developed by Mastersand PhD-level epidemiologists.

  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.


Reasons to buy

  • Develop business strategies by understanding the trends shaping and driving the global ALS market.

  • Quantify patient populations in the global ALS market to improve product design, pricing, and launch plans.

  • Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for ALS therapeutics in each of the markets covered.

EpiCast Report: Amyotrophic Lateral Sclerosis - Epidemiology Forecast to 2023

Table of Contents

1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 6

2 Introduction 7
2.1 Catalyst 7
2.2 Upcoming Reports 7

3 Epidemiology 8
3.1 Disease Background 8
3.2 Risk Factors and Comorbidities 8
3.3 Global Trends 9
3.3.1 US 10
3.3.2 5EU 11
3.3.3 Japan 13
3.4 Forecast Methodology 13
3.4.1 Sources Used 14
3.4.2 Sources Not Used 17
3.4.3 Forecast Assumptions and Methods 18
3.5 Epidemiological Forecast for Amyotrophic Lateral Sclerosis (2013-2023) 21
3.5.1 Diagnosed Prevalent Cases of ALS 21
3.5.2 Age-Specific Diagnosed Prevalent Cases of ALS 22
3.5.3 Sex-Specific Diagnosed Prevalent Cases of ALS 24
3.5.4 Age-Standardized Diagnosed Prevalence of ALS 26
3.6 Discussion 27
3.6.1 Epidemiological Forecast Insight 27
3.6.2 Limitations of the Analysis 28
3.6.3 Strengths of the Analysis 29

4 Appendix 30
4.1 Bibliography 30
4.2 About the Authors 33
4.2.1 Epidemiologists 33
4.2.2 Reviewers 33
4.2.3 Global Director of Epidemiology and Health Policy 34
4.2.4 Global Head of Healthcare 35
4.3 About GlobalData 36
4.4 About EpiCast 36
4.5 Disclaimer 37

List of Tables

Table 1: Risk Factors and Comorbidities for ALS 9
Table 2: Incidence (Cases per 100,000 Population) of ALS in the US, as Reported in Epidemiological Studies 10
Table 3: Prevalence (Cases per 100,000 Population) of ALS in the US, as Reported in Epidemiological Studies 11
Table 4: Incidence (Cases per 100,000 Population) of ALS in the European Markets, as Reported in Epidemiological Studies 12
Table 5: Prevalence (Cases per 100,000 Population) of ALS in the European Markets, as Reported in Epidemiological Studies 12
Table 6: El Escorial Diagnostic Criteria for ALS 13
Table 7: 7MM, Sources of Diagnosed Prevalence Data Used to Forecast the Diagnosed Prevalent Cases of ALS 14
Table 8: 7MM, Diagnosed Prevalent Cases of ALS, Age ?40 Years, Both Sexes, N, 2013-2023 21
Table 9: 7MM, Diagnosed Prevalent Cases of ALS, by Age, Both Sexes, N, (Row %), 2013 23
Table 10: 7MM, Diagnosed Prevalent Cases of ALS, by Sex, Age ?40 years, N (Row %), 2013 25

List of Figures

Figure 1: 7MM, Diagnosed Prevalent Cases of ALS, Age ?40 Years, Both Sexes, N, 2013-2023 22
Figure 2: 7MM, Diagnosed Prevalent Cases of ALS, by Age, Both Sexes, N, 2013 24
Figure 3: 7MM, Diagnosed Prevalent Cases of ALS, by Sex, Age ?40 Years, N, 2013 25
Figure 4: 7MM, Age-Standardized Diagnosed Prevalence (%) of ALS, Age ?40 Years, 2013 27

  • Global Biopolar Disorder Therapeutics Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 19-Oct-2018        Price: US 3480 Onwards        Pages: 137
    Bipolar disorder, also known as manic depression, is a mental disorder that could lead to periods of depression and elevated mood. The treatment of bipolar disorder includes psychotherapy as well as medications such as mood stabilizers and antipsychotics. Scope of the Report: This report focuses on the Biopolar Disorder Therapeutics in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes ......
  • Global Epilepsy Therapeutic Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023
    Published: 12-Oct-2018        Price: US 3480 Onwards        Pages: 145
    Epilepsy is characterized by recurrent seizures caused by the improper balance between inhibitory and excitatory signals in the brain. The symptoms of epilepsy, caused by brain malformations and tumors, birth trauma, and high-risk pregnancies, can be benign or life-threatening. A majority of epilepsy cases have an unknown etiology. Scope of the Report: This report studies the Epilepsy Therapeutic market status and outlook of Global and major regions, from angles of players,......
  • 2018-2023 Global Epilepsy Therapeutics Market Report (Status and Outlook)
    Published: 11-Oct-2018        Price: US 6990 Onwards        Pages: 119
    In this report, LP Information studies the present scenario (with the base year being 2017) and the growth prospects of global Epilepsy Therapeutics market for 2018-2023. Epilepsy is a chronic neurological disorder that cause recurrent unprovoked seizures, characterized by brief and undetectable episodes of involuntary movement involving either a body part (partial) or the entire body (generalized). Neurological disorders treatment market is growing at a significant rate, d......
  • Global Neurodegenerative Diseases Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 02-Oct-2018        Price: US 3480 Onwards        Pages: 135
    Neurodegenerative diseases are becoming increasingly prevalent due to an aging population, but this diverse therapy area remains largely untreatable with current therapies. Neurodegenerative diseases are characterized by neuronal death within the brain and/or central nervous system (CNS), leading to progressive decline in functional neurological capacities. It has a devastating effect on quality of life and independence, often requiring full-time care during the later disease stages. ......
  • Global Traumatic Brain Injury Partnering 2012 to 2018
    Published: 01-Oct-2018        Price: US 1995 Onwards        Pages: 100
    "Delivery of this report will take 1-3 days after purchase." Provides comprehensive understanding and unprecedented access to the thaumatic brain injury partnering deals and agreements entered into by the worlds leading healthcare companies. The Global Traumatic Brain Injury Partnering Terms and Agreements since 2012 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies. -......
  • Global Motor Neurone Disease Partnering 2012 to 2018
    Published: 01-Oct-2018        Price: US 1995 Onwards        Pages: 150
    "Delivery of this report will take 1-3 days after purchase." Provides understanding and access to the motor neurone disease partnering deals and agreements entered into by the worlds leading healthcare companies. The Global Motor Neurone Disease Partnering Terms and Agreements since 2012 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies. - Trends in partnering deals......
  • Global Migraine Partnering 2012 to 2018
    Published: 01-Oct-2018        Price: US 1995 Onwards        Pages: 150
    "Delivery of this report will take 1-3 days after purchase." Provides understanding and access to the migraine partnering deals and agreements entered into by the worlds leading healthcare companies. The Global Migraine Partnering Terms and Agreements since 2012 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies. - Trends in partnering deals - Top deals by value......
  • Global Epilepsy Partnering 2012 to 2018
    Published: 01-Oct-2018        Price: US 1995 Onwards        Pages: 150
    "Delivery of this report will take 1-3 days after purchase." Provides understanding and access to the epilepsy partnering deals and agreements entered into by the worlds leading healthcare companies. The Global Epilepsy Partnering Terms and Agreements since 2012 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies. - Trends in partnering deals - Top deals by value......
  • Global Stroke Partnering 2012 to 2018
    Published: 01-Oct-2018        Price: US 1995 Onwards        Pages: 150
    "Delivery of this report will take 1-3 days after purchase." Provides understanding and access to the stroke partnering deals and agreements entered into by the worlds leading healthcare companies. The Global Stroke Partnering Terms and Agreements since 2012 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies. - Trends in partnering deals - Top deals by value......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs